MY168531A - Medicament form for release of active ingredients - Google Patents
Medicament form for release of active ingredientsInfo
- Publication number
- MY168531A MY168531A MYPI2014003551A MYPI2014003551A MY168531A MY 168531 A MY168531 A MY 168531A MY PI2014003551 A MYPI2014003551 A MY PI2014003551A MY PI2014003551 A MYPI2014003551 A MY PI2014003551A MY 168531 A MY168531 A MY 168531A
- Authority
- MY
- Malaysia
- Prior art keywords
- medicament
- core
- active ingredient
- medicament form
- release
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 6
- 239000004480 active ingredient Substances 0.000 title abstract 4
- 210000004051 gastric juice Anatomy 0.000 abstract 2
- 230000002051 biphasic effect Effects 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention is concerned with the provision of medicament forms which enable effective administration of a medicament which is usually taken twice or more daily by way of a single daily dose. This is achieved in accordance with the invention by provision of a medicament form comprising a core, a gastric juice-resistant intermediate layer disposed on the surface of the core, and a shell disposed on the opposite side of the intermediate layer from the core. Both the core and the shell comprise a proportion of an active ingredient. The active ingredient is released in at least biphasic form from the medicament form, the first phase relating to the immediate release of the active ingredient after ingestion into the gastric juice. The present invention additionally relates to a process for producing the medicament form and to uses thereof. FIG. 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012105528.9A DE102012105528A1 (en) | 2012-06-25 | 2012-06-25 | Pharmaceutical form for the release of active substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY168531A true MY168531A (en) | 2018-11-12 |
Family
ID=48656002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014003551A MY168531A (en) | 2012-06-25 | 2013-06-24 | Medicament form for release of active ingredients |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP2679216B1 (en) |
| AU (1) | AU2013283473B2 (en) |
| BR (1) | BR112014032578B1 (en) |
| CA (1) | CA2877190C (en) |
| CO (1) | CO7250447A2 (en) |
| DE (1) | DE102012105528A1 (en) |
| DK (1) | DK2679216T3 (en) |
| EA (1) | EA030871B1 (en) |
| ES (2) | ES2607447T3 (en) |
| HU (2) | HUE025739T2 (en) |
| IL (1) | IL236466B (en) |
| IN (1) | IN2014MN02526A (en) |
| MX (1) | MX367284B (en) |
| MY (1) | MY168531A (en) |
| PH (1) | PH12014502836A1 (en) |
| PL (2) | PL2863896T3 (en) |
| PT (2) | PT2679216E (en) |
| UA (1) | UA118836C2 (en) |
| WO (1) | WO2014001267A2 (en) |
| ZA (1) | ZA201409506B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2936740C (en) | 2014-10-31 | 2017-10-10 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| ES2862209T3 (en) | 2017-07-20 | 2021-10-07 | Intas Pharmaceuticals Ltd | Solid non-pulsatile prolonged-release oral compositions containing betahistine |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| DE102018129419A1 (en) | 2018-11-22 | 2020-05-28 | Johannes Gutenberg-Universität Mainz | Acrylate copolymer for pharmaceutical applications |
| AU2023366929A1 (en) | 2022-10-25 | 2025-05-08 | Veradermics, Incorporated | Compositions and methods of use for modified release minoxidil |
| DE102023002336A1 (en) * | 2023-06-09 | 2024-12-12 | euvorio GmbH | Carbohydrate-containing compositions in dragee form |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503031A (en) * | 1982-12-17 | 1985-03-05 | Glassman Jacob A | Super-fast-starting-sustained release tablet |
| IT1229237B (en) * | 1989-05-08 | 1991-07-26 | Prodotti Formenti | SALTS OF (2- (PYRIDYL) ETHYL) METHYLAMINE |
| ES2051658T3 (en) * | 1992-08-06 | 1998-06-16 | Gergely Gerhard | EFFERVESCENT TABLETS EASY TO MANAGE. |
| HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
| US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| IT1309591B1 (en) | 1999-03-05 | 2002-01-24 | Formenti Farmaceutici Spa | COMPOSITIONS WITH BETAISTINE CONTROLLED RELEASE. |
| DE10010509A1 (en) | 2000-03-08 | 2001-09-13 | Dresden Arzneimittel | Oral pharmaceutical formulations with controllable release characteristics, e.g. rapid or delayed release, contain sucrose fatty acid ester as drug release controlling agent |
| DE10104880A1 (en) | 2001-01-31 | 2002-08-08 | Roehm Gmbh | Multiparticulate pharmaceutical form, containing at least two differently coated pellet forms |
| EP1493435B1 (en) * | 2003-07-04 | 2008-05-14 | FARMACEUTICI FORMENTI S.p.A. | Controlled Release Compositions of Betahistine |
| US20060280795A1 (en) * | 2005-06-08 | 2006-12-14 | Dexcel Pharma Technologies, Ltd. | Specific time-delayed burst profile delivery system |
| ES2393814T3 (en) * | 2007-04-04 | 2012-12-28 | Sigmoid Pharma Limited | An oral pharmaceutical composition |
| EP2675435A1 (en) * | 2011-02-17 | 2013-12-25 | Lupin Limited | Sustained release composition of memantine |
-
2012
- 2012-06-25 DE DE102012105528.9A patent/DE102012105528A1/en not_active Ceased
-
2013
- 2013-06-24 CA CA2877190A patent/CA2877190C/en active Active
- 2013-06-24 IN IN2526MUN2014 patent/IN2014MN02526A/en unknown
- 2013-06-24 WO PCT/EP2013/063162 patent/WO2014001267A2/en not_active Ceased
- 2013-06-24 EA EA201500044A patent/EA030871B1/en unknown
- 2013-06-24 PL PL13730597T patent/PL2863896T3/en unknown
- 2013-06-24 EP EP13173438.6A patent/EP2679216B1/en active Active
- 2013-06-24 HU HUE13173438A patent/HUE025739T2/en unknown
- 2013-06-24 PT PT131734386T patent/PT2679216E/en unknown
- 2013-06-24 EP EP13730597.5A patent/EP2863896B1/en active Active
- 2013-06-24 HU HUE13730597A patent/HUE031246T2/en unknown
- 2013-06-24 ES ES13730597.5T patent/ES2607447T3/en active Active
- 2013-06-24 PT PT137305975T patent/PT2863896T/en unknown
- 2013-06-24 ES ES13173438.6T patent/ES2546172T3/en active Active
- 2013-06-24 MY MYPI2014003551A patent/MY168531A/en unknown
- 2013-06-24 UA UAA201500502A patent/UA118836C2/en unknown
- 2013-06-24 DK DK13173438.6T patent/DK2679216T3/en active
- 2013-06-24 MX MX2014015660A patent/MX367284B/en active IP Right Grant
- 2013-06-24 AU AU2013283473A patent/AU2013283473B2/en active Active
- 2013-06-24 PL PL13173438T patent/PL2679216T3/en unknown
- 2013-06-24 BR BR112014032578-2A patent/BR112014032578B1/en active IP Right Grant
-
2014
- 2014-12-19 PH PH12014502836A patent/PH12014502836A1/en unknown
- 2014-12-23 ZA ZA2014/09506A patent/ZA201409506B/en unknown
- 2014-12-25 IL IL236466A patent/IL236466B/en active IP Right Grant
-
2015
- 2015-01-15 CO CO15007542A patent/CO7250447A2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502836B1 (en) | Medicament form for release of active ingredients | |
| HK1221646A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX366159B (en) | Self-regulated release of active pharmaceutical ingredient. | |
| JP2015057451A5 (en) | ||
| JP2015523407A5 (en) | ||
| TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
| CL2014002935A1 (en) | Method to treat a human patient with multiple sclerosis with laquinimod, at a daily dose of about 1.2mg; an oral unit dosage form of 1.2 mg of laquinimod and a carrier | |
| WO2015020943A3 (en) | Digestive enzyme composition suitable for enteral administration | |
| WO2011159100A3 (en) | Anti-cancer pharmaceutical composition | |
| PH12020550806A1 (en) | Core tablet composite preparation comprising mosapride and rabeprazole | |
| PH12014501408A1 (en) | Immediate release multi unit pellet system | |
| HK1223825A1 (en) | Stabilized pharmaceutical dosage forms comprising atrasentan | |
| PH12015500653A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| MX363699B (en) | Co-micronisation product comprising ulipristal acetate. | |
| HK1225972A1 (en) | Use of laquinimod to delay huntington's disease progression | |
| WO2016108572A3 (en) | Composition for preventing and treating cholesterol-related diseases | |
| PH12013500980A1 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
| GR1008228B (en) | Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof | |
| MY187270A (en) | Renal insufficiency progression inhibitor, prophylactic agent for renal insufficiency and indoxyl sulfate production inhibitor | |
| WO2011163321A3 (en) | Composition and method of treating lipid encapsulated virus infections | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| TW201613606A (en) | Therapeutic drug for chronic renal failure | |
| JP2013079218A5 (en) | ||
| IN2012CH05549A (en) | ||
| TH104149B (en) | Pharmaceutical form for release of active ingredients |